Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02186119 · ClinicalTrials.gov registry record · Phase 2
A Study of Abicipar Pegol in Patients With Diabetic Macular Edema
A Phase 2 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 151
- Enrollment target
NCT02186119: Completed Phase 2 study, sponsored by Allergan.
NCT02186119 is a Phase 2 study that has completed, run by Allergan. The registered enrollment target is 151 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (14% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02186119, a Phase 2 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 151 participants
- Enrollment target
Study Summary
This is a safety and efficacy study of abicipar pegol in patients with diabetic macular edema.
Interventions
- DRUG ranibizumab
- DRUG abicipar pegol
- OTHER sham procedure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2014-07 |
| Est. Completion | 2015-06 |
| Phase | Phase 2 |
What the finished NCT02186119 record still lists
NCT02186119 is an interventional study that assigns participants to a tested intervention. The registered 151 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (14% higher).
The record links to 0 conditions, and to 3 interventions - of which ranibizumab is the first listed.
NCT02186119 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02186119 about?
NCT02186119 is a clinical study titled "A Study of Abicipar Pegol in Patients With Diabetic Macular Edema". This is a safety and efficacy study of abicipar pegol in patients with diabetic macular edema.
What is the current status of trial NCT02186119?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 151 participants. The study started on 2014-07. Estimated completion is 2015-06.
What interventions are being tested in trial NCT02186119?
The interventions under investigation include: ranibizumab (DRUG), abicipar pegol (DRUG), sham procedure (OTHER).
Who is sponsoring clinical trial NCT02186119?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02186119's enrollment target sits among peer trials
151 454th of 2000 higher than 1,546 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01409161 · 151 participants · Phase 2
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
- NCT04245397 · 151 participants · Phase 1
Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
- NCT05761223 · 151 participants · Phase 1
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
- NCT07195656 · 151 participants · NA
Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia